Unlike other cancer types in which predictive biomarkers exist for targeted therapies (e.g., HER2/neu in breast cancer), therapeutic decision-making in RCC relies on rudimentary and largely clinical measures including performance status, past treatments and histology. Here, ERBB2 is linked to renal cell carcinoma.